Literature DB >> 29406508

Tertiary patenting on drug-device combination products in the United States.

Reed F Beall1, Aaron S Kesselheim1.   

Abstract

Year:  2018        PMID: 29406508     DOI: 10.1038/nbt.4078

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Evolution of insulin patents and market exclusivities in the USA.

Authors:  Jing Luo; Aaron S Kesselheim
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-06       Impact factor: 32.069

2.  Why is there no generic insulin? Historical origins of a modern problem.

Authors:  Jeremy A Greene; Kevin R Riggs
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

3.  Combination products: modernizing the regulatory paradigm.

Authors:  Nina L Hunter; Rachel E Sherman
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

4.  EpiPen price hike comes under scrutiny.

Authors:  Rita Rubin
Journal:  Lancet       Date:  2016-09-24       Impact factor: 79.321

5.  Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?

Authors:  Reed F Beall; Jason W Nickerson; Warren A Kaplan; Amir Attaran
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

  5 in total
  2 in total

1.  Novelty of Active Ingredients in High-Cost Brand-Name Drugs.

Authors:  Emily H Jung; Ameet Sarpatwari; Aaron S Kesselheim
Journal:  J Gen Intern Med       Date:  2020-01-02       Impact factor: 5.128

Review 2.  In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products.

Authors:  Ross L Walenga; Andrew H Babiskin; Liang Zhao
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.